For the readers interested in the stock health of Denali Therapeutics Inc. (DNLI). It is currently valued at $38.55. When the transactions were called off in the previous session, Stock hit the highs of $41.69, after setting-off with the price of $41.69. Company’s stock value dipped to $38.51 during the trading on the day. When the trading was stopped its value was $41.74.Recently in News on January 10, 2022, Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022. Key data readouts to include additional Phase 1/2 data on DNL310 (ETV:IDS) in MPS II (Hunter syndrome) and the first clinical data on DNL919 (ATV:TREM2), both potentially further validating Denali’s Transport Vehicle (TV) platform; in addition, first Phase 1b data in ALS on DNL343, Denali’s small molecule eIF2B activator. You can read further details here
Denali Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $47.47 on 01/03/22, with the lowest value was $38.51 for the same time period, recorded on 01/12/22.
Denali Therapeutics Inc. (DNLI) full year performance was -49.41%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Denali Therapeutics Inc. shares are logging -54.10% during the 52-week period from high price, and -1.93% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $39.31 and $83.98.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 525198 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Denali Therapeutics Inc. (DNLI) recorded performance in the market was -13.57%, having the revenues showcasing -13.95% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.98B, as it employees total of 360 workers.
Specialists analysis on Denali Therapeutics Inc. (DNLI)
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 48.43, with a change in the price was noted -10.39. In a similar fashion, Denali Therapeutics Inc. posted a movement of -21.23% for the period of last 100 days, recording 488,549 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for DNLI is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: Denali Therapeutics Inc. (DNLI)
Raw Stochastic average of Denali Therapeutics Inc. in the period of last 50 days is set at 0.23%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 0.40%. In the last 20 days, the company’s Stochastic %K was 12.99% and its Stochastic %D was recorded 14.65%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -13.57%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -39.97%, alongside a downfall of -49.41% for the period of the last 12 months. The shares increased approximately by -13.47% in the 7-day charts and went up by -15.61% in the period of the last 30 days. Common stock shares were lifted by -13.95% during last recorded quarter.